KEYNOTE-057: Outcomes for Patients With BCG-Unresponsive NMIBC Who Do Not Respond to Pembrolizumab

Roger Li, MD, of Moffitt Cancer Center, describes his post hoc analysis and findings regarding patients with BCG–unresponsive, high-risk non–muscle-invasive bladder cancer who demonstrated non-response to pembrolizumab in the KEYNOTE-057 study.

View his previous comments on Final Results of CORE-001: Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC With CIS.